Albertsons Companies Earnings Call Transcripts
Fiscal Year 2027
-
Q2 identical sales fell 0.8%, while adjusted EBITDA was $784 million and adjusted EPS was $0.36. Leadership is accelerating cost cuts and a business review, with a comprehensive turnaround plan and multi-year outlook due by the Q4 call.
-
Identical sales declined 0.8% year-over-year, with digital and pharmacy growth offset by core business pressures. The company launched the ACI Edge model to drive efficiency and expects $200 million in annual benefits by 2027, while updating guidance to reflect a challenging demand environment.
Fiscal Year 2026
-
The meeting approved all board proposals, including director elections, auditor ratification, and governance amendments, while a shareholder proposal on human rights policy failed. Leadership changes, a 13% dividend increase, and a new regional operating model were announced. FY 2025 saw strong financials, with strategic investments planned for FY 2026.
-
Q4 and FY25 results exceeded expectations despite pharmacy headwinds, with strong digital and loyalty growth, disciplined capital allocation, and a raised productivity target. FY26 guidance anticipates modest sales growth, margin resilience, and continued investment in technology and stores.
-
Q3 2025 delivered 2.4% identical sales growth and 21% digital sales growth, with strong pharmacy and digital performance. Guidance for fiscal 2025 was narrowed, reflecting pharmacy headwinds, but productivity and AI initiatives are driving margin improvement and long-term growth.
-
Identical sales grew 2.8% year-over-year, led by pharmacy and digital, while adjusted EBITDA and EPS declined. FY2025 guidance was raised for sales growth, with continued investments in value, technology, and productivity expected to drive sequential improvement in grocery units and long-term growth.
Fiscal Year 2025
-
Q4 saw 2.3% ID sales growth, strong digital and pharmacy gains, and $855M adjusted EBITDA. Fiscal 2025 guidance targets 1.5%-2.5% ID sales growth and $3.8B-$3.9B adjusted EBITDA, with continued investment in digital, loyalty, and productivity initiatives.
-
Q3 2024 saw 2% identical sales growth, strong digital and pharmacy gains, and a 25% dividend hike. Guidance for Adjusted EBITDA and EPS was raised, with productivity and technology investments driving efficiency. Cautious consumer trends and competitive pressures persist.